Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Young Children With Functional Constipation: a Prospective Comparative Study (BC-LGG-FC)

November 16, 2026 updated by: Biruni University

Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Children Aged 12-48 Months With Functional Constipation: A Prospective, Open-Label, Three-Arm Comparative Study

This prospective study compared Bacillus clausii and Lactobacillus rhamnosus GG, each added to dietary management, with dietary management alone in children aged 12-48 months with functional constipation (Rome IV). Children assigned to probiotic treatment were randomly allocated to Bacillus clausii or Lactobacillus rhamnosus GG (2 × 10⁹ spores or CFU daily for two months); consecutive children receiving dietary management alone served as controls. Defecation frequency, stool consistency, painful defecation and abdominal distension were assessed at baseline and at months 1 and 2.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This prospective, open-label, three-arm comparative study was conducted at the pediatric gastroenterology outpatient clinic of Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, between February 2020 and July 2021.

Allocation: Children assigned to probiotic treatment were randomly allocated in a 1:1 ratio to the Bacillus clausii (BC) or Lactobacillus rhamnosus GG (LGG) group according to a computer-generated randomization list. The control group consisted of consecutive eligible children who presented during the same period and received dietary management alone; this group was not part of the randomization. No placebo was used, and caregivers and investigators were aware of group assignment.

Interventions: Children in the BC group received an oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial (Enterogermina®, Sanofi S.p.A., Italy), one vial once daily. Children in the LGG group received oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops (Maflor®, Mamsel İlaç San. ve Tic. A.Ş., Türkiye), 12 drops once daily (2 × 10⁹ CFU/day). Both probiotics were administered for two months. All children, including those in the control group, received an individualized, age- and weight-appropriate fiber-rich diet plan together with advice on age-appropriate fluid intake. No laxatives or other pharmacological treatments for constipation were given.

Assessments: Weekly defecation frequency (caregiver stool diary), stool consistency (modified Bristol Stool Form Scale for children), painful defecation and abdominal distension were recorded at baseline and at months 1 and 2. Adherence to the probiotic and dietary recommendations was assessed by caregiver report at each follow-up visit.

Outcomes: The primary outcomes were weekly defecation frequency and the presence of painful defecation at month 2. Secondary outcomes were weekly defecation frequency at month 1, stool consistency at months 1 and 2, painful defecation at month 1 and abdominal distension at months 1 and 2.

Study Type

Interventional

Enrollment (Actual)

154

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey (Türkiye), 34295
        • Department of Pediatrics, Faculty of Medicine, Biruni University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 4 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 12 to 48 months
  • Functional constipation according to the Rome IV criteria for infants and toddlers (criterion G7): at least two of the following for at least one month: two or fewer defecations per week; history of excessive stool retention; history of painful or hard bowel movements; history of large-diameter stools; presence of a large fecal mass in the rectum. In toilet-trained children, at least one episode per week of incontinence after the acquisition of toileting skills and a history of large-diameter stools that may obstruct the toilet were also considered.
  • Written informed consent from a parent or legal guardian

Exclusion Criteria:

  • Organic cause of constipation (Hirschsprung disease, anorectal malformation, hypothyroidism, celiac disease, or a spinal or neuromuscular disorder)
  • Developmental delay
  • Previous gastrointestinal surgery
  • Use of probiotics, laxatives or antibiotics within the preceding 8 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bacillus clausii + dietary management

Bacillus clausii oral suspension, 2 × 10⁹ spores (one 5-mL vial) once daily for 2 months, in addition to individualized dietary management.

Oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial; one vial once daily for 2 months.

Other Names:
  • Enterogermina

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

Experimental: Lactobacillus rhamnosus GG + dietary management

Lactobacillus rhamnosus GG oral drops, 2 × 10⁹ CFU (12 drops) once daily for 2 months, in addition to individualized dietary management.

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

Oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops; 12 drops once daily (2 × 10⁹ CFU/day) for 2 months.

Other Names:
  • Maflor
Active Comparator: Dietary management alone

Individualized dietary management without a probiotic. Consecutive eligible children presenting during the same period; not randomized.

Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weekly defecation frequency
Time Frame: 2 months after the start of treatment

Number of bowel movements per week, recorded from a stool diary kept by the caregiver.

2 months after the start of treatment
Proportion of children with painful defecation
Time Frame: 2 months after the start of treatment

Presence or absence of painful defecation, based on caregiver report at the follow-up visit

2 months after the start of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weekly defecation frequency
Time Frame: 1 month after the start of treatment

Number of bowel movements per week, recorded from a stool diary kept by the caregiver.

1 month after the start of treatment
Stool consistency (modified Bristol Stool Form Scale for children)
Time Frame: 1 month and 2 months after the start of treatment

Caregiver-rated stool form using the modified Bristol Stool Form Scale for children; higher scores indicate softer stools.

1 month and 2 months after the start of treatment
Proportion of children with painful defecation
Time Frame: 1 month after the start of treatment

Presence or absence of painful defecation, based on caregiver report at the follow-up visit.

1 month after the start of treatment
Proportion of children with abdominal distension
Time Frame: 1 month and 2 months after the start of treatment

Presence or absence of abdominal distension, assessed at the follow-up visit.

1 month and 2 months after the start of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: ABDULLAH SERT, Department of Pediatrics, Faculty of Medicine, Biruni University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2020

Primary Completion (Actual)

July 1, 2021

Study Completion (Actual)

July 20, 2021

Study Registration Dates

First Submitted

November 16, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • KAEK-151-2019
  • Ethics decision 151/2019 (Other Identifier: Taksim Training and Research Hospital Clinical Research Ethics Committee)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data underlying the reported results will be available from the corresponding author upon reasonable request.

IPD Sharing Time Frame

Beginning after publication of the article, with no planned end date.

IPD Sharing Access Criteria

De-identified individual participant data underlying the reported results will be available to researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author (asert@biruni.edu.tr); data will be shared after approval of the request and a data-sharing agreement.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.